Tibet Weixinkang Medicine Co Ltd (603676) — Capital Reinvestment Ratio
Tibet Weixinkang Medicine Co Ltd (603676) has a Capital Reinvestment Ratio of 1.36x as of September 2025, meaning it reinvests 1% of its operating cash flow (CN¥13.68 Million) in capital expenditures (CN¥18.57 Million). See debt-free asset ratio of Tibet Weixinkang Medicine Co Ltd to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Tibet Weixinkang Medicine Co Ltd Capital Reinvestment Ratio (2013–2024)
This chart tracks Tibet Weixinkang Medicine Co Ltd's Capital Reinvestment Ratio across 12 annual periods. Check 603676 cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Tibet Weixinkang Medicine Co Ltd (2013–2024)
Year-by-year Capital Reinvestment Ratio for Tibet Weixinkang Medicine Co Ltd from 2013 to 2024. For live market cap and broader valuation context, see market cap of Tibet Weixinkang Medicine Co Ltd.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.16x | CN¥372.78 Million | CN¥58.18 Million | ▼ -43.4% |
| 2023 | 0.28x | CN¥256.67 Million | CN¥70.81 Million | ▼ -12.6% |
| 2022 | 0.32x | CN¥246.15 Million | CN¥77.69 Million | ▼ -3.1% |
| 2021 | 0.33x | CN¥170.69 Million | CN¥55.60 Million | ▼ -19.9% |
| 2020 | 0.41x | CN¥133.70 Million | CN¥54.35 Million | ▼ -1.0% |
| 2019 | 0.41x | CN¥106.34 Million | CN¥43.65 Million | ▼ -63.9% |
| 2018 | 1.14x | CN¥83.17 Million | CN¥94.50 Million | ▼ -7.5% |
| 2017 | 1.23x | CN¥63.30 Million | CN¥77.76 Million | ▲ +382.9% |
| 2016 | 0.25x | CN¥103.79 Million | CN¥26.40 Million | ▼ -32.7% |
| 2015 | 0.38x | CN¥114.47 Million | CN¥43.29 Million | ▼ -36.9% |
| 2014 | 0.60x | CN¥118.47 Million | CN¥70.97 Million | ▼ -45.4% |
| 2013 | 1.10x | CN¥88.59 Million | CN¥97.29 Million | — |